A multistep therapy with subcutaneous low dose recombinant interleukin- 2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: A pilot study

Biomedicine and Pharmacotherapy

Volumn 52, Issue 7-8, 1998, Pages 311-316

  Nicolini, A ^a   Carpi, A ^a   Ferrari, P ^a   Sagripanti, A ^a   Anselmi, L ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Colorectal cancer; Fluorouracil; Metastases

Indexed keywords

FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 2;

ADULT; AGED; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032405734     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(98)80027-9     Document Type: Conference Paper

References (20)

1. 1 Advanced colorectal meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence of terms of response rate. J Clin Oncol 1992 ; 10 : 896-903
2. 2 Atzpodien J, Kirchner H, Hanninen EL et al. European studies of interleukin-2 in metastatic renal carcinoma. Semin Oncol 1994 ; 6 : 22-6
3. 3 Blanke CD, Kasimis B, Schein P, Capizzi R, Kurman M. Phase II study of trimetrexate, fluorouracil and leucovorin for advanced colorectal cancer. J Clin Oncol 1997 ; 15 : 915-20
4. 4 Conti JA, Kemeny NE, Saltz LB et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996 ; 14 : 709-15
5. 5 Decarli A, La Vecchia C, Negri E et al. Cancer mortality in Italy, 1989, and an overview of trends from 1955 to 1989. Tumori 1993 ; 79 : 151-65
6. 6 Hansen RM. Systemic therapy in metastatic colorectal cancer. Arch Intern Med 1990; 150 : 2265-9
7. 7 Jager E, Heike M, Bernhard H et al. Weekly high dose leucovorin versus low dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J Clin Oncol 1996 ; 14 : 2274-9
8. 8 Kemeny N. Role of chemotherapy in the treatment of colorectal carcinoma. Semin Surg Oncol 1987 ; 3 : 194-214
9. 9 Kohne CH, Schoffski P, Wilke H et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24 hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998 ; 16 : 418-26
10. 10 Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989 ; 7 : 425-32
11. 11 Lopez M, Di Lauro L, Gionfra T. Thymopentin and interleukin-2 in combination with 5-fluorouracil and leucovorin in metastatic colorectal carcinoma; preliminary results. J Surg Oncol 1991 ; 2 suppl 2 : 108-11
12. 12 Meta-analysis group in cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16 : 301-8
13. 13 Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981 ; 47 : 207-14
14. 14 Mœitel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994 ; 330 : 1136-41
15. 15 Nicolini A, Carpi A, Di Marco G, Giuliani L, Giordani R, Palla S. A rationale post-operative follow-up with carcinoembrionic antigen, tissue polypeptide antigen and urinary hydroxiproline in breast cancer patients. Cancer 1989; 63: 2037-46
16. 16 Nicolini A, Ferdeghini M, Colizzi C. Evaluation of CEA-TPA-CA15.3-CA549 and TPS in the monitoring of metastatic breast cancer. J Nucl Biol Med 1993 ; 37 : 126-33
17. 17 Nicolini A, Caciagli M, Zampieri F et al. Usefulness of CEA-TPA-GICA-CA72.4 and CA195 in the diagnosis of primary colorectal cancer and at its relapse. Cancer Det Prev 1995 ; 19 : 183-95
18. 18 Scheithauer W, Kornek G, Marczell A et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol 1997 ; 15 : 908-14
19. 19 Seymour MT, Slevin ML, Kerr DJ et al. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. J. Clin Oncol 1996 ; 14 : 2280-8
20. 20 Web HJ, Wilke HJ, Dierlanua J et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24 hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994 ; 5 : 233-7